FEV1 % predicted · children with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · children with cystic fibrosis
1 finding from 1 review
Ocular chlamydia trachomatis infection · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Antibiotic resistance · people (any age) with active trachoma
Oral azithromycin led to lower antibiotic resistance Proportion of samples showing evidence of… compared with control; GRADE not reported.
1 finding from 1 review
Adverse effects · people (any age) with active trachoma
1 finding from 1 review
Active trachoma · people (any age) with active trachoma
1 finding from 1 review
Ocular chlamydia trachomatis infection · people (any age) with active trachoma
1 finding from 1 review
Antibiotic resistance · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Adverse effects · people (any age) with active trachoma
1 finding from 1 review
Active trachoma · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
Time to next pulmonary exacerbation · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Hospital admissions · adults and children with cystic fibrosis
1 finding from 1 review
New acquisition of CF pathogens: PA · adults and children with cystic fibrosis
1 finding from 1 review
Need for additional antibiotics: participants needing extra IV antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
QoL · adults and children with cystic fibrosis
1 finding from 1 review
Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous and mucocutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous and mucocutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found